NEWS

NEWS

Total 79

69
NeoImmuneTech’s NT-I7 Creates a More Immunogenic Tumor Microenvironment when Associated with Pembrolizumab
2022-09-13
68
NeoImmuneTech Welcomes New Members to its Scientific Advisory Board
2022-08-08
67
NeoImmuneTech to Present at Cytokine-Based Drug Development Summit
2022-07-26
66
FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for the treatment of Glioblastoma Multiforme
2022-07-13
65
QUARTERLY UPDATE (2Q 2022)
2022-07-12
64
Interest of Combining NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) with Pembrolizumab keeps Growing
2022-07-04
63
NeoImmuneTech to Display its Environmental, Social, and Governance Activities on its Corporate Website
2022-06-30
62
A Study in Nature Communications Reports that NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity
2022-06-15
61
NeoImmuneTech to Present at Upcoming BIO International Convention
2022-06-13
60
NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors
2022-06-07

1 2 3 4 5 >>>